[go: up one dir, main page]

ATE406452T1 - Retrovirale vektoren - Google Patents

Retrovirale vektoren

Info

Publication number
ATE406452T1
ATE406452T1 AT97909438T AT97909438T ATE406452T1 AT E406452 T1 ATE406452 T1 AT E406452T1 AT 97909438 T AT97909438 T AT 97909438T AT 97909438 T AT97909438 T AT 97909438T AT E406452 T1 ATE406452 T1 AT E406452T1
Authority
AT
Austria
Prior art keywords
dependent
hiv
rev
transcription unit
provirus
Prior art date
Application number
AT97909438T
Other languages
English (en)
Inventor
Susan Mary Kingsman
Alan John Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE406452T1 publication Critical patent/ATE406452T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
AT97909438T 1996-10-17 1997-10-17 Retrovirale vektoren ATE406452T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9621679.1A GB9621679D0 (en) 1996-10-17 1996-10-17 Improved retroviral vectors

Publications (1)

Publication Number Publication Date
ATE406452T1 true ATE406452T1 (de) 2008-09-15

Family

ID=10801597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909438T ATE406452T1 (de) 1996-10-17 1997-10-17 Retrovirale vektoren

Country Status (8)

Country Link
US (2) US20020141978A1 (de)
EP (1) EP0931157B1 (de)
JP (1) JP2001502904A (de)
AT (1) ATE406452T1 (de)
AU (1) AU4712497A (de)
DE (1) DE69738944D1 (de)
GB (2) GB9621679D0 (de)
WO (1) WO1998017817A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076715B1 (de) 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentivirale Verpackungszellen
CA2331782A1 (en) 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
CA2365901A1 (en) 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2001036614A2 (de) 1999-11-16 2001-05-25 Geneart Gmbh Gessellschaft Für Angewandte Biotechnologie Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306631A (en) * 1987-08-21 1994-04-26 University Of Colorado Foundation, Inc. Compositions and method for inhibition of HIV production
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
CA2109579A1 (en) * 1991-05-29 1992-12-10 Julianna Lisziewicz Eukaryotic expression vectors with regulation of rna processing
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same

Also Published As

Publication number Publication date
US20020141978A1 (en) 2002-10-03
WO1998017817A1 (en) 1998-04-30
AU4712497A (en) 1998-05-15
DE69738944D1 (de) 2008-10-09
GB9904143D0 (en) 1999-04-14
EP0931157B1 (de) 2008-08-27
GB9621679D0 (en) 1996-12-11
EP0931157A1 (de) 1999-07-28
GB2331989A (en) 1999-06-09
GB2331989B (en) 2000-09-27
US20060024279A1 (en) 2006-02-02
JP2001502904A (ja) 2001-03-06

Similar Documents

Publication Publication Date Title
Lavrentieva et al. High polymorphism level of genomic sequences flanking insertion sites of human endogenous retroviral long terminal repeats
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
Ling et al. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells
WO2001071042A3 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
NO20001497D0 (no) Ekspresjon av endogene gener ved ikke-homolog rekombinasjon av en vektorkonstrukt med cellulært DNA
EP0385558A3 (de) Materialien und Verfahren für "genome walking"
Klasens et al. Inhibition of polyadenylation by stable RNA secondary structure
WO2003008575A3 (en) Dna sequences for regulating transcription
ATE406452T1 (de) Retrovirale vektoren
ATE91715T1 (de) Genexpressionssystem.
ATE427959T1 (de) Gereinigtes sr-p70 protein
ATE272711T1 (de) Neuartige expressionsvektoren
DE69323199D1 (de) Gen für die ataxia-telangiectasia komplementationsgruppe d
Tajima et al. Mutant tax protein from bovine leukemia virus with enhanced ability to activate the expression of c-fos
DE68912228D1 (de) Verfahren für die Rettung von DNS und für den Nachweis von Mutationen in Markiergenen.
SE8604636L (sv) Sett att uttrycka gener med hjelp av bacillus brevis
ATE72837T1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
Mischiati et al. Characterization of a major histocompatibility complex class II X-box-binding protein enhancing tat-induced transcription directed by the human immunodeficiency virus type 1 long terminal repeat
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
CA2289907A1 (en) Eukaryotic and retroviral antisense initiator elements
Lembo et al. Trans-activation of the mouse cytomegalovirus immediate early gene enhancer by ras oncogenes
Peberdy Genetic engineering in relation to enzymes.
DK561889A (da) Ekspressionsforstaerker samt anvendelse heraf til forhoejelse af udbyttet ved ekspression af rekombinante gener
EP0962533A3 (de) Auf Zucker reagierende Enhancer-Sequenzen aus alpha-Amylasegenen
ATE250670T1 (de) Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0931157

Country of ref document: EP